CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its third quarter 2010 financial results on Thursday, October 28, 2010 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) its Hedgehog pathway inhibitor program under collaboration with Genentech, (ii) CUDC-101, Debio 0932 and its other targeted cancer programs, (iii) its financial results as of and for the three- and nine-month periods ended September 30, 2010, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
